CAPR U.S. FDA advisers vote against evidence of effectiveness of Capricor's duchenne heart disease therapy deramiocel
CAPR U.S. FDA advisers vote against evidence of effectiveness of Capricor's duchenne heart disease therapy deramiocel
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.